SCM
TBPH icon

Scopia Capital Management’s Theravance Biopharma TBPH Stock Holding History

Scopia Capital Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-75,000
Closed -$2.39M – 40
2014
Q2 		$2.39M Buy
+75,000
New +$2.26M 0.06% 32

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
FAM
Foundation Asset Management White Plains, New York $116M AUM 31.02% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Scopia Capital Management's TBPH Position: Q3 2014 in Review

Scopia Capital Management sold out of Theravance Biopharma (TBPH) in Q3 2014, closing a stake of 75,000 shares — an estimated $2.39M sold.

Scopia Capital Management first reported a position in TBPH in Q2 2014 and held it in 1 quarter. The position peaked at $2.39M in Q2 2014. 91 funds tracked by Wall St. Rank hold TBPH as of Q3 2014.

  • Scopia Capital Management reported no remaining Theravance Biopharma position as of Q3 2014 after selling out during the quarter.
  • Scopia Capital Management sold 75,000 Theravance Biopharma shares in Q3 2014, an estimated $2.39M.
  • Scopia Capital Management first reported a position in Theravance Biopharma in Q2 2014 and held it in 1 quarter.
  • Scopia Capital Management's Theravance Biopharma position peaked at $2.39M in Q2 2014.
  • 91 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2014.

Based on Scopia Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.